Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

Proteintech Group, Inc.. (10/20/20). "Press Release: Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools". Chicago, IL & Munich.

Organisations Organisation Proteintech Group Inc.
  Group Proteintech (Group)
  Organisation 2 ChromoTek GmbH
  Group Proteintech (Group)
Products Product nanobody (general, camelid antibody)
  Product 2 research antibody
Index term Index term ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group
Persons Person Jung, Marion (T-Curx 202402– COO before ChromoTek Managing Director + Co-Founder + Earlybird Ventures)
  Person 2 Li, Jason (Proteintech 202010 CEO)
     


Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies.

ChromoTek is the market leader in nanobodies — high-performance recombinant reagents used for breakthrough research discoveries. The combined companies will better address the industry’s growing opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.

“Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers,” said Dr. Marion Jung, CEO of ChromoTek. “It is exciting to be working together with a company that shares our common values in reproducibility and quality for the benefit of research and beyond.”

Dr. Jason Li, CEO of Proteintech said, “This new partnership will deliver considerable value to the market. With global manufacturing across three continents, not only will we serve the research market better, but we’ll also deeply impact translational science and therapeutic applications.”


About Proteintech Group

Proteintech, founded in 2002, is a leading manufacturer of antibodies, proteins and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. With over 70,000 publications and confirmed specificity, Proteintech offers antibodies and immunoassays across research areas. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001-2015 accredited. To learn more about Proteintech, please visit www.ptglab.com.


About ChromoTek

ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid Nanobodies. In contrast to traditional antibodies, Nanobodies consist of only one single polypeptide chain; they are the smallest known antibodies. The company has a unique experience in the development of Nanobodies with desired affinities, specificities, and formats for dedicated applications in biomedical research where other antibody formats fail. As a market and product leader for high performing reagents, we are proud contributing to breakthrough research discoveries around the world. In addition, ChromoTek is a trusted service provider of custom-made Nanobodies for the pharmaceutical industry. Founded in 2008, ChromoTek has offices in Martinsried (Germany) near Munich and Islandia (NY, USA).


Contacts

Thompson + Conard Communications
Jane Thompson
jane@thompsonconard.com
1-415-710-1675

   
Record changed: 2023-06-05

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Proteintech (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top